Mutations C677T and A1298C of the 5,10-methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease

Blood Coagulation and Fibrinolysis

Volumn 13, Issue 5, 2002, Pages 423-431

  Domagala, T B ^a   Adamek, L ^a   Nizankowska, E ^a   Sanak, M ^a   Szczeklik, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Acquired risk factors; Factor V Leiden; G20210A prothrombin gene variant; Homocysteine; MTHFR gene polymorphisms; Venous thromboembolic disease

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE; CYSTEINE; HOMOCYSTEINE; THREONINE;

AGED; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC STRAIN; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

3' UNTRANSLATED REGIONS; ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMINO ACID SUBSTITUTION; CODON; FACTOR V; FASTING; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION, MISSENSE; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POINT MUTATION; POLAND; PROTHROMBIN; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0036630169     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200207000-00007     Document Type: Article

References (52)

1. Resistance to activated protein C and venous thromboembolism
2. Activated protein C resistance: From phenotype to genotype and clinical practice
3. A common genetic variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
4. Polymorphisms of folate and cobalamin metabolism
5. Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase
6. Thermolabile methylenetetrahydrofolate reductase: An inherited risk factor for coronary artery disease
7. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
8. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia
9. A second mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects?
10. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme acitvity
11. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations
12. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis
13. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
14. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
15. Hyperhomcystinemia and deep-vein thrombosis
16. Plasma homocysteine in venous thromboembolism
17. Plasma homocysteine levels in patients with deep venous thrombosis
18. A second mutation of the methylenetetrahydrofolate reductase gene and the risk of venous thrombotic disease
19. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: Incidence and effect of combined genotypes on plasma fasting and postmethionine load homocysteine in vascular disease
20. Prevalence of methylenetetrahydrofolate reductase mutations in patients with venous thrombosis
21. 506)
22. Retinal arterial occlusion in a child with factor V Leiden and thermolabile methylene tetrahydrofolate reductase mutations
23. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine and glutathione in human plasma
24. Rapid two-stage PCR for detecting factor V G1691A mutation
25. Mutation A1298C of methylenetetrahydrofolate reductase: Risk for early coronary disease not associated with hyperhomocysteinemia
26. Homocyst(e)ine, diet and cardiovascular disease
27. Factor V Leiden (G1691A), the prothrombin 3′-untranslated region variant (G20210A) and thermolabile methylenetetrahydrofolate reductase (C677T): A single genetic test genotypes all three loci determination of frequencies in the S. Wales population of the UK
28. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR
29. Primary thrombophilla in Mexico. II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos
30. A common mutation in methylenetetrahydrofolate reductase is associated with an increased risk of venous thrombosis
31. The mutation ALA677-VAL in the methylenetetrahydrofolate reductase gene: A risk factor for arterial and venous thrombosis
32. Single and combined prothrombic factors in patients with idiopathic venous thromboembolism, prevalence and risk asessment
33. C677T mutation of the 5,10-methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in thrombotic vascular disease
34. Effect of the MTHFR C677T variant on risk of venous thromboembolism: Interaction with factor V Leiden and prothrombin (F2G20210A) mutations
35. Coexpression of inherited risk factors thrombophilia, lipoprotein(a) and homocysteine
36. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep vein thrombosis
37. The C677T MTHFR variant and the risk of venous thrombosis
38. Venous disease
39. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study
40. Major lifestyle determinants of plasma total homocysteine distribution: The Hordaland Homocysteine Study
41. Coffee consumption and plasma total homocysteine: The Hordaland Homocysteine Study
42. Lifestyle factors and plasma homocysteine concentrations in general population sample
43. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population
44. Homocysteine and cysteine: Determinants of plasma levels in middle-aged and elderly subjects
45. Plasma total homocysteine in healthy subjects: Sex-specific relation with biological traits
46. Prevalence of moderate hyperhomocysteinemia in patients with early-onset juvenile venous and arterial occlusive disease
47. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase
48. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia
49. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: Association with plasma total homocysteine and folate concentrations
50. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A 20210 mutation
51. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism
52. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes